Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders

American Journal of Clinical Pathology

Volumn 125, Issue 5, 2006, Pages 651-653

  Greiner, Timothy C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA; IMATINIB; PROTEIN TYROSINE KINASE;

ASSAY; CANCER DIAGNOSIS; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIAGNOSTIC TEST; DNA SEQUENCE; EDITORIAL; GENE; GENE MUTATION; HUMAN; HUMAN CELL; JAK2 GENE; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION;

EID: 33646240825     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/NXXTGRCXD0TMA3C2     Document Type: Editorial

References (12)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:17794790.
5. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
6. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
7. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006;125:625-633.
8. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
9. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168-171.
10. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350-353.
11. Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. Hematology (Am Soc Hematol Educ Program). 2005:201-208.
12. Tefferi A, Pardanani A. Mutation screening for JAK2(V617F): When to order the test and how to interpret the results. Leuk Res. 2006. E pub. PMID# 16460800.